Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane alternative dosing in ER-positive breast cancer
NCT02598557Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of exemestane in breast cancer, sponsored by National Cancer Institute. Started Dec 2016; status: completed.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02598557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598557.